ACA
BRNS

Arena Capital Advisors’s Barinthus Biotherapeutics BRNS Stock Holding History

Arena Capital Advisors’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-30,698
Closed -$341K – 303
2021
Q4 		$341K Hold
30,698
– – 0.03% 207
2021
Q3 		$483K Hold
30,698
– – 0.04% 217
2021
Q2 		$515K Buy
+30,698
New +$454K 0.04% 278

Other funds holding BRNS

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
MGIM
M&G Investment Management London, United Kingdom $28.2B AUM 25.87% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.5B AUM 13.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IIM
Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Arena Capital Advisors's BRNS Position: Q1 2022 in Review

Arena Capital Advisors sold out of Barinthus Biotherapeutics (BRNS) in Q1 2022, closing a stake of 30,698 shares — an estimated $341K sold.

Arena Capital Advisors first reported a position in BRNS in Q2 2021 and held it in 3 quarters. The position peaked at $515K in Q2 2021. 12 funds tracked by Wall St. Rank hold BRNS as of Q1 2022.

  • Arena Capital Advisors reported no remaining Barinthus Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Arena Capital Advisors sold 30,698 Barinthus Biotherapeutics shares in Q1 2022, an estimated $341K.
  • Arena Capital Advisors first reported a position in Barinthus Biotherapeutics in Q2 2021 and held it in 3 quarters.
  • Arena Capital Advisors's Barinthus Biotherapeutics position peaked at $515K in Q2 2021.
  • 12 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q1 2022.

Based on Arena Capital Advisors's 13F filing for Q1 2022, filed 13 May 2022.